Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12454692 | 0.82 | CACNA2D1 (0.48) | POLBKIF11MEN1KMT2AKDM4E | |
| SCHEMBL6525429 | 0.81 | PDE4A (0.51) | POLBKIF11MEN1KMT2AKDM4E | |
| SCHEMBL5555016 | 0.80 | PDE4A (0.41) | POLBKIF11MEN1KMT2AKDM4E | |
| SCHEMBL3838937 | 0.79 | KIF11 (0.40) | POLBKIF11MEN1KMT2AKDM4E | |
| SCHEMBL4028286 | 0.79 | MEN1 (0.46) | POLBKIF11MEN1KMT2AKDM4E | |
| SCHEMBL5356314 | 0.78 | KIF11 (0.40) | POLBKIF11MEN1KMT2AKDM4E | |
| SCHEMBL5100445 | 0.78 | KIF11 (0.62) | KIF11 | |
| SCHEMBL5100270 | 0.78 | KIF11 (0.51) | POLBKIF11MEN1KMT2AKDM4E | |
| SCHEMBL3837879 | 0.77 | MEN1 (0.41) | POLBKIF11MEN1KMT2AKDM4E | |
| SCHEMBL4046310 | 0.76 | KIF11 (0.53) | POLBKIF11MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234080-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234080-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIFC1 | POLB 391/4885KIF11 9/4885MEN1 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.